Brind.

Needham & Company and Morgan Stanley upgraded Cytokinetics' rating and target price on November 9, 2026.

1 report, 1 independent Updated Mon 00:00

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Cytokinetics

Keep exploring

The entities involved

Cytokinetics
company in South San Francisco, United States
- MarketBeat is aggregating consensus ratings for Cytokinetics, while Bank of America provided a neutral rating and Morgan Stanley raised its target price.Wed 08:34

Coverage

Newest first; wire copies grouped

Mon 00:00dailypolitical.com